M Christina Cox, Luciano Castiello, Mauro Mattei, Laura Santodonato, Giuseppina D'Agostino, Elena Muraro, Debora Martorelli, Caterina Lapenta, Arianna Di Napoli, Francesca Di Landro, Michela Cangemi, Antonio Pavan, Paolo Castaldo, Stefan Hohaus, Simona Donati, Enrica Montefiore, Cinzia Berdini, Davide Carlei, Domenica M Monque, Luigi Ruco, Daniela Prosperi, Agostino Tafuri, Francesca Spadaro, Paola Sestili, Massimo Spada, Riccardo Dolcetti, Stefano M Santini, Carmela Rozera, Eleonora Aricò, Imerio Capone, Filippo Belardelli
PURPOSE: This study was aimed at evaluating the feasibility, safety, immunologic and clinical responses in patients with follicular lymphoma treated with monocyte-derived dendritic cells generated in the presence of IFNα and GM-CSF (IFN-DC) in combination with low doses of rituximab. PATIENTS AND METHODS: Firstly, we analyzed in vitro and in vivo the immunologic properties of IFN-DC against follicular lymphoma. Thus, we performed a phase I trial in 8 patients with refractory and relapsed follicular lymphoma based on sequential intranodal injections of low-dose of rituximab and unloaded IFN-DC and report the safety, clinical, and immunologic results of the enrolled patients...
September 1, 2019: Clinical Cancer Research